The expression of EGFL7 is associated with tumor grade, pathological type and prognosis for patients with glioma.

EGFL7 binds with EGFRwt, but not EGFRvIII. EGFL7 activated the downstream pathways of EGFRwt, and enhanced it's oncogenicity.

EGFR depleted β-catenin/TCF4 complex, promoted EGFL7 transcription, and maintained a continuous EGFL7 autocrine flow line.

FH535, a β-catenin/TCF4 inhibitor, attenuated oncogenicity of GBM cells by suppressing EGFL7 transcription activity.